LOS ANGELES, CA - VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as chief financial officer, effective immediately. The move is expected to strengthen the company's financial leadership as it advances its proprietary BiTAC(R) technology platform and oncology pipeline.
Willener brings over three decades of international financial leadership experience, spanning global capital markets, investment banking, corporate finance, asset management, and strategic leadership. He will report to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to play a key role in supporting the company's capital strategy and strategic opportunities.
Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG before being appointed CFO in 2025, where he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management.
This appointment comes at a critical time for VERAXA, which is focused on building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond, guided by rigorous quality-by-design principles.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company's BiTAC(R) technology is a registered trademark of VERAXA Biotech GmbH.
The addition of a seasoned financial executive like Willener is likely to reassure investors and stakeholders about the company's commitment to robust financial management as it navigates the complex landscape of oncology drug development. With his extensive experience in capital markets and asset management, Willener is expected to help VERAXA secure the necessary funding and strategic partnerships to advance its pipeline.
For more information on VERAXA and its latest news, visit the company's newsroom at https://ibn.fm/VRXA. To view the full press release, visit https://nnw.fm/jcHOU.
Forward-looking statements in this article involve risks and uncertainties, and actual results may differ materially. These statements are subject to factors beyond management's control, including those discussed in the company's filings with the SEC. Undue reliance should not be placed on forward-looking statements, which are based on information available as of the date hereof.
